Istituto Superiore di Sanità
Rosa Maria Martoccia
Istituto Superiore di Sanità
299, Viale Regina Elena
00161 - Roma (I)
Phone: +39 06 4990 2266
Fax: +39 06 49 38 71 32
ipil@iss.it
Intellectual Property Portolio
The patent is the legal instrument conferring the author of an invention the temporary monopoly of exploitation of the invention itself, i.e. the right to exclude a third party from realizing the invention and thriving on it. The patent represents, therefore, a legal monopoly, even if territorially and temporarily limited.
Sort...
|
Code |
Title | Principal Inventor | Technology | Status (1) | Assignee |
|---|---|---|---|---|---|
1 |
Peptides and uses thereof for therapy of celiac Disease. |
De Vincenzi M. |
Biopharmaceuticals |
A |
ISS |
2 |
Subunit vaccines and processes for the production thereof. |
Giorgi C. |
Vaccine technologies |
A |
34% ISS, 33% ENEA, 33% IFO |
3 |
Vaccines including as an adjuvant type I IFN and processes related thereto. |
Belardelli F. |
Vaccine technologies |
A |
50% ISS, 50% EJ |
4 |
Method for generating highly active human dendritic cells from monocytes. |
Belardelli F. |
Cell technologies |
A |
ISS |
5 |
Fusion protein, chimeric viral particles displaying it on the capsid, plants infected with said particles, their uses and compositions comprising them. |
Belardelli F. |
Vaccine technologies |
A |
50% ISS, 50% ENEA |
8 |
Methods of treating inflammatory bowel disease using cholera toxin B subunit. |
Boirivant M. |
Biopharmaceuticals |
L |
50% ISS, 50% NIH |
9 |
Induction of up-regulation of CTLA-4 in T lymphocytes. |
De Magistris M. |
Cell-based therapies |
A |
ISS |
11 |
Stem cell factor for preventing chemotherapy induced depletion of blood cells. |
De Maria R. |
Re-styled drugs |
L |
ISS |
12 |
Novel use of proton pump inhibitors as both anti-neoplastic agents and revertant of human tumors. |
Fais S. |
Re-styled drugs |
L |
ISS |
18 |
Detection of pathological prionic protein in the olfactory epithelium of subjects affected by sporadic Creutzfeld-Jacob disease. |
Pocchiari M. |
Diagnostics |
A |
ISS |
19 |
Composition and method of imparting resistivity to HIV superinfection to cells. |
Federico M. |
Research products |
L |
50% ISS, 50% Molmed |
23 |
Monoclonal antibodies to E. coli 026 produced by cell line. |
Caprioli A. |
Diagnostics |
L |
ISS |
26 |
A new colorectal tumor associated antigen COA-1. |
Maccalli C. |
Biomarker |
A |
50% ISS, 50% NIH |
27 |
Use of biologically active HIV-1 TAT, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases. |
Ensoli B. |
Vaccine technologies |
A |
ISS |
29 |
Use of inhibitors of the protease of the human immunodeficiency virus (HIV) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith. |
Ensoli B. |
Re-styled drugs |
A |
ISS |
30 |
HIV-1 TAT, or derivatives thereof, for prophylactic and therapeutic vaccination. |
Ensoli B. |
Vaccine technologies |
A |
ISS |
31 |
Nanoparticles for delivery of a pharmacologically active agent. |
Ensoli B. |
Delivery Systems |
A |
ISS |
32 |
Vaccines containing HIV Tat as adjuvant. |
Ensoli B. |
Vaccine technologies |
A |
ISS |
33 |
Use of microparticles for antigen delivery. |
Ensoli B. |
Delivery Systems |
A |
ISS |
34 |
Novel TAT complexes and vaccines comprising them. |
Ensoli B. |
Vaccine technologies |
A |
ISS |
37 |
Toxin-related polypeptides with antimicrobial and antiviral activity. |
Cassone A. |
Biopharmaceuticals |
O* |
40% ISS, 30% UNISI, 30% INV |
38 |
Glucan-based vaccines. |
Cassone A. |
Vaccine technologies |
L |
INV |
39 |
Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation. |
Spadafora C. |
Re-styled drugs |
L |
ISS |
43 |
Peptides adjuvant. |
De Magistris M. |
Vaccine technologies |
L |
INV |
44 |
Peptides for delivery of mucosal vaccines. |
De Magistris M. |
Vaccine technologies |
L |
50% ISS, 50% Univ. del Maryland |
45 |
Antiglucan antibodies. |
Cassone A. |
Vaccine technologies |
L |
INV |
46 |
Domain antibodies (for Candida's secretory aspartyl proteinase 2). |
Cassone A. |
Vaccine technologies |
O |
INV |
47 |
Therapeutic (Fusion protein comprising HIV-I Nef mutant and its use in therapy and diagnosis). |
Federico M. |
Biopharmaceuticals |
A |
ISS |
49 |
Improved replication competent adenoviral vectors. |
Ensoli B. |
Delivery Systems |
L |
25% ISS, 75% NIH |
50 |
Endothelial autoantigen, methods and uses for therapy and diagnosis of autoimmune diseases. |
Ortona E. |
Biopharmaceuticals |
A |
ISS |
51 |
Treatment of cognitive and learning impairment. |
Diana G. |
Biopharmaceuticals |
A |
ISS |
53 |
Mathematical method to determine the vasal blood flow. |
Grigioni M. |
Software |
A |
ISS |
54 |
Dermonecrotizing protein factors of bacterial origin and related uses in medical field (Analgesic activity towards inflammatory pain). |
Malorni W. |
Biopharmaceuticals |
A |
50% ISS, 50% CNR |
56 |
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. |
Migliaccio G. |
Cell-based therapies |
A |
ISS |
57 |
MicroRNA based therapies for kit-based tumors. |
Peschle C. |
DNA/RNA |
A |
ISS |
58 |
Retrotransposon inhibition in therapy. |
Spadafora C. |
DNA/RNA |
L |
66% ISS, 34% INV |
60 |
Method for induction of proliferation of partially or totally non-proliferating cells. |
Crescenzi M. |
Cell-based therapies |
A |
ISS |
61 |
Salmonella enterica strains of reduced pathogenicity, method for their preparation and uses thereof. |
Pasquali P. |
Animal Health |
A |
45% ISS, 55% Univ. Tor Vergata |
62 |
Rapid generation of activated mononuclear antigen presenting cells from monocytes. |
Belardelli F. |
Cell-based therapies |
A |
ISS |
63 |
Digestive system cancer stem cells and tests and uses therefor (Colon Cancer Stem Cells for diagnostic and cancer treatment purposes). |
De Maria R. |
Cancer Stem Cells |
A |
ISS |
64 |
A novel passive vaccine for candida infection. |
Cassone A. |
Vaccine technologies |
A |
50%ISS, 50% UNITO |
65 |
Antisense oligonucleotides against hypophyseal pro-opiomelanocortin and their medical use to prevent and treat post-traumatic stress syndrome. |
Loizzo A. |
DNA/RNA |
A |
86,67% ISS, 6,67% Spampinato, 6,66% Campana |
66 |
Elisa test to detect in human serum antibodies against virus SV40. |
Rezza G. |
Diagnostics |
A |
50%ISS, 50% UNIFE |
67 |
Medicaments for fungal infections ( Novel Antigens). |
Cassone A. |
Vaccine technologies |
L |
ISS |
68 |
Novel disease treatments (for multiple sclerosis). |
Aloisi F. |
Vaccine technologies |
A |
ISS |
69 |
Megakaryopoiesis control by a pathway involving miR. |
Peschle C. |
DNA/RNA |
A |
ISS |
70 |
Use of antisense RNA in methods of replacement of defective monocytes and dendritic cell production. |
Peschle C. |
DNA/RNA |
A |
ISS |
71 |
Apparatus for transmission of ECG. |
Censi F. |
Medical Device |
A |
ISS |
72 |
Cancer Stem Cells (Lung Cancer Stem cells for diagnostic and cancer treatment purposes). |
De Maria R. |
Cancer Stem Cells |
A |
ISS |
73 |
Truncated secretory aspartyl proteinase 2 (SAP2). |
Cassone A. |
Vaccine technologies |
L |
50%ISS, 50% PEVION |
74 |
Industrial process for the production of the biologically active Tat protein. |
Ensoli B. |
Vaccine technologies |
A |
50% ISS, 50% UNIURB |
75 |
Kit ligand treatment of ß-thalassemia. |
Peschle C. |
DNA/RNA |
A |
ISS |
76 |
New method for the generating of human dendritic cells endowed with optimal functional properties for the induction of cross-priming. |
Belardelli F. |
Vaccine technologies |
A |
ISS |
78 |
Medical equipment to reveal small tumors in the diagnosis of breast cancer through molecular imaging with radionuclides |
Garibaldi F. |
Medical Device/Equipment |
A |
ISS |
79 |
miR-146 and CXCR4 receptor (antisense RNA vs. CXCR4 for cancer and rheumatoid arthritis). |
Peschle C. |
DNA/RNA |
A |
ISS |
80 |
Somatically acquired JAK1 mutations in acute lymphoblastic leukemia. |
Tartaglia M. |
Biopharmaceuticals |
A |
ISS |
81 |
Down-regulation of thymosin-ß-4 promotes neuronal differentiation of neural progenitors cells. |
Merlo D. |
Biopharmaceuticals |
A |
ISS |
83 |
Phospho-proteomic analysis of cancer stem cells |
Signore M. |
Biomarkers |
A |
50% ISS, 50% GMU |
84 |
Compositions containing terpinen-4-ol for treatmnent and prevention of mastitis in milk producing animals. |
Aureli P. |
Animal Health |
A |
60% ISS, 20% INRA, 20% IZSLT |
85 |
Bioinformatic method to identify proteic markers of pathological statuses. |
Facchiano F. |
Software |
A |
INV |
86 |
Steps counter based on gastrocnemious muscular expansion. |
Macellari V. |
Medical Device |
A |
INV |
87 |
Device for mechanical stimulation of foot in walking rehabilitation. |
Macellari V. |
Medical Device |
A |
INV |
88 |
Sensor & biosensor apparatus for toxicity indexes in industrial food production. |
Frazzoli C. |
Food Technology |
A |
ISS |
89 |
Biomarkers for breast cancer. |
Camerini S. |
Biomarker |
O |
50% ISS, 50% GMU |
90 |
Colorectal cancer biomarkers. |
Camerini S. |
Biomarker |
A |
50% ISS, 50% GMU |
91 |
Methods of isolating analytes from a sample. |
Luchini A. |
Diagnostics |
O |
50% ISS, 50% GMU |
92 |
Inhibition of thymosin-ß-4 to decrease growth of colon cancer stem cells. |
Merlo D. |
Biopharmaceuticals |
A |
ISS |
93 |
Method for detecting and controlling cancer. |
Pierbon M. |
Biomarker |
A |
50% ISS, 50% GMU |
94 |
Assay for Metastatic colorectal cancer. |
Pierbon M. |
Biomarker |
L |
50% ISS, 50% GMU |
95 |
Human monoclonal antibodies in scFv format with neutralization activity against Influenza H5N1 |
Ascione A. |
Biopharmaceuticals |
A |
ISS |
96 |
AMPK Pathway as a theranostic indicator for mixed lineage leukemia (MLL) |
Accordi B. |
Theranostic |
A |
50% ISS, 50% GMU |
97 |
Discovery of signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease |
Pierbon M. |
Theranostic |
O |
50% ISS, 50% GMU |
(1) Legenda: A = available; L = Licensed; O= Option to License *: Licence granted for veterinary use only; human use available.
Abbreviations and Achronyms:
EJ - Edward Jenner Institute for Vaccine Research
ENEA - Ente per le Nuove Tenologie, l'Energia e l'Ambiente
GMU - George Mason University
IFO - Istituti Fisioterapici Ospitalieri
INRA - Institut National de la Recherche Agronomique
INV - Inventori
ISS - Istituto Superiore di Sanità
IZSLT - Istituto Zooprofilattico Sperimentale del Lazio e Toscana
NIH - National Institute of Health
PEVION - Pevion Biotech Ltd.
UNIFE - Università degli Studi di Ferrara
UNISI - Università degli Studi di Siena
UNITO - Università degli Studi di Torino
UNIURB - Università degli Studi di Urbino "Carlo Bo"
